Small molecule · Inhibitor of Janus-associated kinase 2 V617F mutant (JAK2V617F) pseudokinase (JH2) domain (JAK2) · developed by Prelude Therapeutics
PRT12396 is an orally bioavailable inhibitor that allosterically binds the pseudokinase (JH2) domain of the mutant JAK2V617F protein, reducing its activation and downstream JAK-STAT signaling while sparing wild-type JAK2. It is being studied in myeloproliferative neoplasms, including polycythemia vera and myelofibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07469891 | Phase 1 | Polycythemia Vera (PV) | Recruiting | PRLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)Polycythemia Vera (PV)Post-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisPrimary Myelofibrosis (PMF)
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.
See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRLD catalysts and pipeline →